Detailed
Compact
Art
Reverse
October 2, 2019
In this podcast episode, Dr. Jim Phelps reviews a meta-analysis about ketamine for suicidal ideation and how effective it is.
September 19, 2019
In this podcast episode we learn the core concepts surrounding ketamine and esketamine; a very hot topic in psychiatry today. We have Dr. Sam Wilkinson and Dr. Joseph Goldberg joining us.
August 28, 2019
In this podcast episode, we dig further into the practical use of pharmacogenetic testing in psychiatric practice. We address its limitations and the resources you can use to guide your decision making.
August 14, 2019
In this podcast episode, we question whether pharmacogenetic testing is valuable in psychiatry practice. Joined by Dr. Simon Kung and Dr. Michael Thase, we find answers to this question!
July 31, 2019
In this podcast interview with Dr. Leslie Citrome, we venture into the topic of transdermal delivery of psychotropics. We explore the challenge of creating patches and also peek into the latest antipsychotics in clinical trials for transdermal delivery.
July 17, 2019
This podcast episode covers the basics of diagnosing and managing novel synthetic opioids and synthetic cathinones.
July 3, 2019
The use of designer drugs (novel psychoactive compounds) is rapidly-growing and dangerous, this podcast episode gives you exactly what you need to know to identify and manage these cases.
June 19, 2019
In this podcast episode, we revisit psychedelics with Dr. David Nutt and Dr. Robin Carhart-Harris. We review how psychedelics work, their potential uses, and adverse effects in managing treatment-resistant depression. We also discuss the use of MDMA in PTSD.
May 31, 2019
In this podcast episode, we explore with Dr. David Nutt (Imperial College London) the serotonin receptors 5-HT1A and 5-HT2A and their links to clinical psychiatry. We particularly focus on their roles in mood, anxiety, psychosis, aggression, and learning.
May 16, 2019
In this podcast episode, we answer the question: What if you can’t use an SSRI for GAD? With expert commentary from Dr. David Osser (Harvard Medical School), we explore different options and also highlight what not to use.
May 3, 2019
In this podcast episode, we cover the treatment algorithm of generalized anxiety disorder. Dr. David Osser (Harvard Medical School) shares practical tips and anecdotes for your practice.
April 17, 2019
In this podcast episode, we investigate the effectiveness of using antipsychotic plasma levels in clinical practice with Dr. Jonathan Meyer (University of California San Diego).
April 8, 2019
In this podcast episode, we learn about prescribing natural medications in psychiatry with Dr. David Mischoulon (Harvard Medical School). We explore the use of melatonin, Valerian and Ginkgo biloba.
March 21, 2019
In this podcast episode, we learn about prescribing natural medications in psychiatry with Dr. David Mischoulon (Harvard Medical School). We explore St. John’s wort, SAM-e, Omega 3 fatty acids and Rhodiola rosea.
March 8, 2019
In this episode, we cover practical tips on the management of fever, cardiovascular and cardiometabolic adverse effects related to clozapine use. Dr. Jonathan Meyer provides evidence-based pearls as well as clinical anecdotes.
February 21, 2019
In this episode, we cover practical tips on the management of sialorrhea, constipation, sedation, and seizures related to clozapine use. Dr. Jonathan Meyer provides evidence-based pearls as well as clinical anecdotes.
February 6, 2019
In this episode we answer the question: Do SSRIs increase the risk of bleeding? We do this with Dr. James Levenson (Virginia Commonwealth University) and we explore GIT, perioperative, CNS and postpartum bleeding with SSRIs.
January 25, 2019
In this episode, we explore the management of common PTSD comorbidities with Prof. David Osser (Harvard Medical School). We cover substance use disorder, depression, psychosis and prescribing in women of childbearing potential.
January 9, 2019
In this episode, we discuss part of Dr. David Osser’s (Harvard Medical School) PTSD algorithm about treating sleep symptoms of PTSD. We cover the evidence on prazosin’s efficacy and trazodone use. The rationale behind certain drugs to avoid is also covered.
December 28, 2018
In this episode, we review principles of prescribing psychotropics in patients with liver, kidney and lung diseases with Dr. James Levenson (Virginia Commonwealth University).
December 14, 2018
In this episode, we learn to prescribe with the gut in mind. Dr. James Levenson (Virginia Commonwealth University) joins us with to-the-point tips on prescribing psychotropics in patients with GI disease as well as exploring how psychotropics can affect the GIT.
November 29, 2018
In this episode, we uncover clinical pearls of geriatric psychopharmacology. We are joined by Dr. Sandra Jacobson of the University of Arizona giving practical tips on prescribing for this special group of patients.
November 15, 2018
In this podcast episode, we take on the challenge of treatment-resistant depression and its therapeutic options. Dr. Philip Cowen (University of Oxford) provided insights for this clinical conundrum with a simple algorithm.
October 30, 2018
In this episode, we venture into the psychopharmacology of agitation, with a special focus on psychotic agitation. Dr. Michael Jibson (University of Michigan) and Dr. David Osser (Harvard Medical School) shared clinical pearls to treat this challenging situation.
October 2, 2018
When is the right time to discontinue an antipsychotic in the treatment of schizophrenia? We reviewed the evidence as well as consulting Dr. Ira Glick to help us answer this question.
August 27, 2018
Dr. Jeffrey Mattes, psychiatrist in Princeton, New Jersey speaks about drug interaction warnings that appear during electronic prescribing and how these warnings may be influenced by drug company promotion. This interview is part of a series covering the 2018 ASCP Annual Meeting.
July 29, 2018
Dr. Robin Carhart-Harris speaks about the use of psilocybin for treatment-resistant depression.  - Psilocybin, a psychedelic, is a 5-HT2A agonist.  Stimulation of the 5-HT2A receptor promotes neural plasticity -A potential mechanism of action of psilocybin in treatment-resistant depression involves “brain resetting” - Psilocybin has a good safety profile. However, patients may experience challenging psychological experiences that may turn out to be frightening for some people
July 29, 2018
At the 2018 Annual Meeting of the American Psychiatric Association, Dr. Robert Patterson (psychiatrist at McLean Hospital Boston) spoke about the benefits of following a structured approach to psychopharmacology. In this episoder, Dr. Patterson explains why algorithms are good for patient outcomes and how they support clear decision making.
    15
    15
      0:00:00 / 0:00:00